,,ii #aahth ,,congress #ast ,session ,s4 #aabj ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,march #cj1 #bjbc,ms4 ,hassan 7for herself and ,mr4 ,braun7 introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,a ,,bill ,to improve the actions available to eligible product developers in the event of delays in receiving covered product for purposes of generic drug or biosimilar biological product development4 #a4 ,short title ,this ,act may be cited as the ,improved ,access to ,affordable ,medications ,act4 #b4 ,amendments to actions for delays of generic drugs and biosimilar biological products ,section #faj of division ,n of the ,further ,consolidated ,appropriations ,act1 #bjbj 7,public ,law #aaf-id2 #ba ,u4,s4,c4 #cee-b7 is amended-- 7#a7 in subsection 7a7-- 7,a7 in paragraph 7#a77;,c7-- 7i7 by inserting or contractual terms after additional conditions2 and 7ii7 by inserting by the license holder after covered product2 7,b7 in paragraph 7#b77;,a77iii71 by striking including any device and inserting including any packaging1 device1 or accessory2 7,c7 by redesignating paragraphs 7#c7 through 7#aj7 as paragraphs 7#d7 through 7#aa71 respectively2 7,d7 by inserting after paragraph 7#c7 the following3 7#d7 the term designated delivery service means any delivery service provided by a trade or business that the ,secretary determines-- 7,a7 is available to the general public throughout the ,united ,states2 7,b7 records electronically to its database1 kept in the regular course of its business1 or marks on the cover in which any item referred to in this section is to be delivered1 the date on which such item was given to such trade or business for delivery2 and 7,c7 provides overnight or #b-;day delivery service throughout the ,united ,states2 2 7,e7 in paragraph 7#f71 as so redesignated1 by inserting including the parent company of such holder after covered product2 and 7,f7 in paragraph 7#aa71 as so redesignated-- 7i7 in subparagraph 7,a71 in the matter preceding clause 7i71 by inserting 1 at any time1 after conduct testing2 and 7ii7 in subparagraph 7,b71 by inserting 1 at any time1 after fulfill2 7#b7 in subsection 7b77#b7-- 7,a7 in subparagraph 7,a77iii7-- 7i7 in the matter preceding subclause 7,i71 by striking a written request to purchase sufficient quantities of the covered product to the license holder1 and such request-- and inserting one or more written requests to purchase sufficient quantities of the covered product to the license holder for the relevant stage of development1 and each such request--2 and 7ii7 in subclause 7,,ii71 by inserting or by a designated delivery service before the semicolon at the end2 and 7,b7 in subparagraph 7,b71 by amending clause 7ii7 to read as follows3 7ii7 ,authorization ,the ,secretary shall1 by written notice1 authorize the eligible product developer to obtain sufficient quantities of an individual covered product subject to a ,,rems with ,,etasu for purposes of development and testing-- 7,i7 in the case of development and testing that does not involve human clinical trials1 not later than #fj days after the date on which a request under clause 7i7 is received1 if the eligible product developer has agreed to comply with any conditions the ,secretary determines necessary2 or 7,,ii7 in the case of development and testing that involves human clinical trials1 not later than #abj days after the date on which a request under clause 7i7 is received1 if the eligible product developer has-- 7aa7 7,,aa7 submitted protocols1 informed consent documents1 and informational materials for testing that include protections that provide safety protections comparable to those provided by the ,,rems for the covered product2 or 7,,bb7 otherwise satisfied the ,secretary that such protections will be provided2 and 7bb7 met any other requirements the ,secretary may establish4 2 and 7#c7 by adding at the end the following3 7h7 ,samples access policy ,not later than #de days after the date of approval of a covered product1 or1 in the case of a covered product approved before the date of enactment of the ,improved ,access to ,affordable ,medications ,act1 not later than #de days after such date of enactment1 each license holder of a covered product shall make available its policy on evaluating and responding to requests submitted under subsection 7b77#b77;,a74 ,such policy shall-- 7#a7 be made public and readily available1 such as by posting such policy on a publicly available website2 and 7#b7 shall include-- 7,a7 contact information for the license holder to facilitate communication about written requests described in subsection 7b77#b77;,a77iii72 7,b7 procedures for making such requests2 7,c7 the address to which such requests should be sent2 7,d7 the official license holder for each marketed product2 and 7,e7 the named corporate officer who is responsible for receiving such requests4 4